2025 | Frontier Medicines

Frontier Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 7, 2026/in 2025, Featured, Press Release/by Paul Simpson

January 7, 2026

Frontier Medicines Announces Publication in Nature Communications Highlighting a Novel Method that Enables Next-Generation Covalent Medicines

January 5, 2026/in 2025, Press Release/by Paul Simpson

January 5, 2026

Frontier Medicines Presents Preclinical Data from Three Programs at the 37th AACR-NCI-EORTC International Conference on Molecular Targets

October 21, 2025/in 2025, Press Release/by David Anderson

October 22, 2025

Frontier Medicines Announces Third Precision Oncology Development Candidate

October 15, 2025/in 2025, Press Release/by eallison

October 14, 2025

Frontier Medicines Announces Publication in Structure Highlighting Novel E3 Ligase DCAF2 can be Harnessed for Targeted Protein Degradation

October 6, 2025/in 2025, Press Release/by eallison

October 3, 2025

Frontier Medicines to Participate in September Investor Conferences

September 1, 2025/in 2025, Press Release/by eallison

August 28, 2025

Frontier Medicines Unveils New Preclinical Data for FMC-220, a First-in-Class Covalent p53 Y220C Activator, at AACR 2025

August 27, 2025/in 2025, Press Release/by eallison

April 28, 2025

Frontier Medicines to Participate in Two Upcoming March Investor Conferences

August 27, 2025/in 2025, Press Release/by eallison

February 27, 2025

Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential

August 27, 2025/in 2025, Press Release/by eallison

January 9, 2025

Frontier Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference

August 27, 2025/in 2025, Press Release/by eallison

January 8, 2025